Treatment Information

Back

Breast Cancer treatment details. Chemotherapy.

Medical Center Alkmaar, Alkmaar, Netherlands.

Survival: monthsCountry:Netherlands
Toxiciy Grade:3City/State/Province:Alkmaar
Treatments:ChemotherapyHospital:Medical Center Alkmaar
Drugs:Journal:Link
Date:Mar 2014

Description:

Patients:
This phase 3 study involved elderly (65 years or older) female metastatic breast cancer patients who were divided into two different treatment groups. Group A consisted of 40 patients, while group B had 38 patients.

Treatment:
Patients in group A were treated with the chemotherapy agent pegylated liposomal doxorubicin (PLD).

Patients in group B received chemotherapy with capecitabine.

Toxicities:
The most severe toxicities in group A were of grade 3 and included fatigue, hand-foot syndrome (skin toxicity), and stomatitis (inflammation of the stomach lining).

There was one treatment-related death due to gastrointestinal bleeding in group B. Grade 3 fatigue, hand-foot syndrome (skin toxicity), and diarrhea were also reported.

Results:
The median overall survival rates in group A and B were 13.8 and 16.8 months, respectively.

Support:
This study was supported by the following pharmaceutical companies: Amgen, Schering Plough, and Janssen Cilag.

Correspondence: Dr. C. H. Smorenburg; email: [email protected]



Back